Mabpro, a biotech company, is developing an immunotherapy platform targeting Carbonic Anhydrase IX (CA IX) to treat aggressive, hypoxic tumors, which account for over half of all cancer deaths. The company is also creating companion diagnostics to enhance patient stratification and improve treatment efficacy in both solid and lymphatic tumors.
Funding
$160K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hypoxic tumors, characterized by low oxygen levels, are aggressive and resistant to conventional cancer treatments, accounting for a significant proportion of cancer-related deaths. Effective therapies are needed to target these tumors and improve patient outcomes. Current patient stratification methods may not accurately identify individuals most likely to benefit from specific treatments.
Solution
Mabpro is developing an immunotherapy platform that targets Carbonic Anhydrase IX (CA IX), an enzyme overexpressed in hypoxic tumors. By targeting CA IX, Mabpro's humanized monoclonal antibodies aim to selectively target and eliminate these aggressive tumor cells. The company is also developing companion diagnostics to improve patient stratification, ensuring that the right patients receive the most effective treatment. This approach aims to enhance treatment efficacy in both solid and lymphatic tumors, potentially improving survival rates for a range of cancer types.
Target Audience
The primary target audience includes cancer patients with hypoxic tumors, oncologists, and healthcare providers seeking more effective and targeted cancer immunotherapies.
Features
- Humanized monoclonal antibodies targeting Carbonic Anhydrase IX (CA IX)
- Companion diagnostics for enhanced patient stratification
- Focus on aggressive, hypoxic tumors
- Potential application in both solid and lymphatic tumors
- Proprietary IP and exclusive license for core background IP related to therapeutic applications of CA IX
- Exploring potential applications outside of cancer, starting with cardiovascular diseases